Following dramatic success in many types of advanced solid tumors, interest in
immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given …

Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Colorectal cancer (CRC) is the third most common tumour in men and the second in women,
accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and …

Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …

Importance Management of colorectal cancer (CRC) has been updated continuously over
the past 2 decades. While the combination of these initiatives has had implications for …

Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

The prognostication of colorectal cancer (CRC) has traditionally relied on staging as defined
by the Union for International Cancer Control (UICC) and American Joint Committee on …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly develo** area …

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most
common cause of cancer death. Predictions of the future burden of the disease inform health …

(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …